<DOC>
	<DOCNO>NCT00502983</DOCNO>
	<brief_summary>Little know epidemiologic risk factor associate development acute myelogenous leukemia ( AML ) , less known role genetic susceptibility play development AML . Researchers conduct population-based study investigate genetic susceptibility adult AML patient , de novo treatment-related well-defined geographical area . Using case-control design , researcher prospectively enroll 400 patient Texas 800 healthy control . Controls recruit use random digit dialing , match case age , gender , ethnicity . Epidemiological demographic information obtain personal interview , integrate clinical information , cytogenetic data , genotypic marker . Blood specimen collect participant , genotyped marker associate activation detoxification chemical carcinogen , include chemotherapy drug . Polymorphisms gene cytochrome p450 ( CYP2E1 ) , glutathione S-transferases ( GSTT1 , GSTM1 , GSTP1 ) , epoxide hydrolase ( HYL1 ) , NADPH-quinone oxidoreductase ( NQO1 ) , myeloperoxidase ( MPO ) analyze . This study provide insight role susceptibility marker , along clinical epidemiological , cytogenetic factor , play identification people risk develop AML . Understanding genetic predisposition exogenous exposure interact determine AML susceptibility allow development prevention strategy future .</brief_summary>
	<brief_title>Molecular Epidemiology Acute Myelogenous Leukemia</brief_title>
	<detailed_description>INFORMED CONSENTS FOR AML PATIENTS : For study , ask complete personal interview . During interview , ask question demographic ( age , sex , etc . ) , chemical may expose , medical history , family history cancer , diet , smoke alcohol use history . It take around 50 minute complete interview . You also around 1 tablespoon blood drawn special test . These test look biologic factor associate AML . The interview blood draw may do regularly schedule visit M. D. Anderson , may schedule time place convenience . You may contact home phone researcher collect information change health status . THIS IS AN INVESTIGATIONAL STUDY . Up 1,200 participant take part study . INFORMED CONSENT FOR CONTROL SUBJECTS : For study , ask complete personal interview . During interview , ask question demographic ( age , sex , etc . ) , chemical may expose , medical history , family history cancer , diet , smoke alcohol use history . It take around 50 minute complete interview . You also around 1 tablespoon blood drawn special test . These test look biologic factor associate AML . The interview blood draw schedule time place convenience . THIS IS AN INVESTIGATIONAL STUDY . Up 1,200 participant take part study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . A histologically confirm diagnosis AML ( patient ) 2 . Aged 18 old 3 . Resident Texas 4 . Willing able provide write informed consent authorization 5 . Willing donate 10mL blood complete personal interview 1 . Under 18 year age 2 . History invasive cancer , exclude nonmelanoma skin cancer ( control )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Epidemiology</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Healthy Control</keyword>
	<keyword>Lifestyle Factors</keyword>
	<keyword>Genetic Susceptibility</keyword>
	<keyword>Interview</keyword>
	<keyword>AML</keyword>
</DOC>